How many acquisitions has Biogen made so far?

Biogen has completed 13 acquisitions so far, with an average acquisition amount of $1.68B.

Which countries does Biogen usually acquire in?

Biogen has made acquisitions in 4 countries with the most activity in United States and United Kingdom.

Which is Biogen's latest acquisition?

Biogen's most recent acquisition is Apellis Pharmaceuticals, a Developer of therapeutics for the treatment of rare diseases, acquired in March 2026 for $5.6B.

Which sectors does Biogen target for acquisitions?

Most of Biogen's acquisitions are in Immunology (4) and Neurology (3).

In which year did Biogen make the most acquisitions?

Biogen was most active in 2006, with 2 acquisitions completed in that year.

List of 13 Acquisitions by Biogen (Apr 2026)

Most viewed in 2019

Biogen has completed 13 acquisitions. Peak acquisition years were 2006 with 2 acquisitions, and 2026 and 2025 each with 1. Activity spans 4 countries: United States (9 acquisitions), United Kingdom (2), and China (1). A total of 12 sectors have been involved, with the most active being Immunology (4), Neurology (3), and Rare Diseases (3). Over the last five years (2020-2025), it averaged 0.6 acquisitions per year. The current calendar year has seen 1 acquisition so far. The most recent acquisition, completed in March 2026, was Apellis Pharmaceuticals for $5.6B. Founded in 2008 and based in Crestwood, Apellis Pharmaceuticals specializes in developing therapeutics for rare diseases.

Here's the year on year acquisition history of Biogen:

Number of Total Acquisitions

Year	# Acquisitions
2026	1
2025	1
2024	1
2023	1
2019	1
2017	1
2015	1
2014	1
2013	1
2007	1
2006	2
2003	1

View all Acquisitions by Biogen

Recent acquisitions by Biogen

Biogen's most recent acquisition - Apellis Pharmaceuticals is a Developer of therapeutics for the treatment of rare diseases, founded in 2008 and located in Crestwood. Biogen acquired it in March 2026 for a price of $5.6B.

Here is the list of all acquisitions by Biogen sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Mar 31, 2026	Apellis Pharmaceuticals	$5.6B	-	32	958
Sep 18, 2025	Alcyone	$85M	-	13	644
May 22, 2024	HIBio	$1.15B	-	12	762
Jul 28, 2023	Reata Pharma	Undisclosed	Lazard, Goldman Sachs ... and 2 more	46	660
Mar 04, 2019	Nightstar	$877M	Goldman Sachs, Ropes & Gray ... and 2 more	22	555